MedTrace Logo

Transurethral Vapor Enucleation Resection of the Prostate (TVERP), Bipolar TURis and HoLEP

NCT04398420 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 29

Last updated 2023-01-09

No results posted yet for this study

Summary

To verify the safety and efficacy of the use of the plasma vaporisation button in Transurethral Vapor Enucleation and Resection of the prostate (TVERP) for treatment of Benign prostatic hypertrophy (BPH) patients with prostate ˃30 and ≤80 ml compare to TURis or HoLEP surgery methods.

Conditions

  • Benign Prostatic Hypertrophy

Interventions

DEVICE

TVERP

Transurethral Vapor Enucleation Resection of the prostate

DEVICE

TURis

Transurethral Vapor Enucleation Resection of the prostate

DEVICE

HoLEP

Transurethral Vapor Enucleation Resection of the prostate

Sponsors & Collaborators

  • Olympus Surgical Technologies Europe

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
22 Years
Max Age
75 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-08-27
Primary Completion
2022-08-01
Completion
2022-08-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04398420 on ClinicalTrials.gov